The MAM domain-containing glycosylphosphatidylinositol anchor 1 (MDGA1) gene, which encodes a protein involved in synaptic inhibition, has been identified as a potential risk gene for restless legs syndrome. A recent study in the Chinese population described increased MDGA1 methylation levels in patients with idiopathic RLS (iRLS) compared to healthy controls. In this study, we investigated the possible association between the most common variants in the MDGA1 gene and the risk for iRLS in a Caucasian Spanish population. We assessed the frequencies of MDGA1 rs10947690, MDGA1 rs61151079, and MDGA1 rs79792089 genotypes and allelic variants in 263 patients with idiopathic RLS and 280 healthy controls using a specific TaqMan-based qPCR assay. We also analyzed the possible influence of the genotype frequencies on several variables, including age at the onset of RLS, gender, a family history of RLS, and response to drugs commonly used in the treatment of RLS. The frequencies of the genotypes and allelic variants of the three common missense SNVs studied did not differ significantly between RLS patients and controls, neither in the whole series nor when analyzing each gender separately; were not correlated with age at onset and the severity of RLS assessed by the International Restless Legs Syndrome Study Group Rating Scale (IRLSSGRS); and were not related to a family history of RLS or the pharmacological response to dopamine agonists, clonazepam, or gabaergic drugs. Our findings suggest that common missense SNVs in the MDGA1 gene are not associated with the risk of developing idiopathic RLS in Caucasian Spanish people.
15 November 2026 in British Journal of Pharmacology
Background and Purpose: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are a leading cause of drug hypersensitivity reactions (HRs), but genetic determinants of individual susceptibility remain unclear. Here, we identified genetic variants in redox‐ and immune‐related pathways associated with cross‐reactive NSAID hypersensitivity (CR‐NSAID) and single‐NSAID–induced urticaria/angioedema/anaphylaxis (SNIUAA) and to characterize their functional relevance. Experimental Approach: A multicentre prospective case–control study was conducted in Spanish individuals of European ancestry, including patients with confirmed NSAID hypersensitivity and NSAID‐tolerant individuals. Single nucleotide variants (SNVs) in redox‐ and immune‐related genes were genotyped using a two‐stage discovery and independent replication design. SNVs showing significant associations were functionally evaluated by measuring serum glutathione S‐transferase (GST), superoxide dismutase (SOD) and aldo‐keto reductase (AKR) activities according to genotype. Key Results: GSTM5 rs11101989 and GSTZ1 haplotype (rs1046428, rs7975, rs7972) associated with increased susceptibility to CR‐NSAID. Functional analyses demonstrated that carriers of the GSTM5 rs11101989 CC genotype had significantly reduced total serum GST activity. In SNIUAA, SOD1 variants (rs2070424 and rs2833483) associated with increased susceptibility and reduced serum SOD activity. Additionally, AKR1C3 rs34186955 increased susceptibility, whereas AKR1C3 rs12529 and IL4R rs1805016 associated with decreased susceptibility. Integration of genetic and functional data supported involvement of redox‐related pathways in distinct NSAID hypersensitivity phenotypes and identified GSTM5 and SOD1 variants as candidate genetic susceptibility markers. Conclusions and Implications: Genetic variability in redox‐related and immune‐regulatory pathways contributed to susceptibility to cross‐reactive and selective NSAID hypersensitivity. These findings support further validation of biomarker‐based strategies for personalized risk assessment and safer NSAID prescribing. Further validation in independent populations is required.
An important role of neuroinflammation in the pathogenesis of Parkinson’s disease (PD) has been proposed. Since some microRNAs (miRNAs), and miR-155 in particular, are involved in neuroinflammatory processes, a previous study reported an association between one of the most common single nucleotide variants (SNVs), rs767649, in the MIR155 gene, and risk for PD. The aim of the current study was to replicate this finding in a larger Spanish population case–control series. We analyzed genotype and allele frequencies of the MIR155 rs767649 SNV in a Spanish Caucasian cohort consisting of 459 PD patients and 460 age- and sex-matched healthy controls, using a TaqMan allelic discrimination assay specifically designed for rs767649. The genotype frequencies of the MIR155 rs767649, under codominant, dominant, recessive, and overdominant inheritance models, as well as allelic frequencies, showed no significant differences between PD patients and healthy controls. Likewise, the age at PD onset did not differ among the three MIR-155 rs767649 genotypes. These data did not identify a statistically significant association between MIR155 rs767649 variants and PD risk. However, the low frequency of the variant allele resulted in limited statistical power, and modest genetic effects cannot be excluded.